Marc Evanchik
Chief Scientific OfficerMr. Marc Evanchik, M.S., was Senior Vice President of Pharmacology and Translational Medicine at Braveheart Bio, Inc. since November 2025 until February 5, 2026 and is its Chief Scientific Officer since January 2026. He leads research and development efforts that connect early scientific discovery with clinical advancement. He is Consultant of Kainomyx, Inc. He has deep expertise in pharmacology and experience developing innovative therapies. Earlier in his career, he helped pioneer the first-in-class therapy mavacamten, a breakthrough treatment targeting the underlying mechanics of hypertrophic cardiomyopathy (HCM). His research demonstrated that modulating cardiac muscle contraction could reduce thickening and stiffness of the heart, laying the foundation for a new approach to treating HCM. He is also an inventor on multiple patents related to novel treatments for heart muscle disorders and cardiac remodeling. He holds a B.S. in Chemistry from the University of California, Santa Cruz and an M.S. in Chemistry from the University of California, Davis.
Positions
- Company NameBraveheart Bio, Inc.Stock CodeBRVEPositionChief Scientific OfficerColleagues
- TMTravis MurdochCEO, President & Director
- CAChristopher A. ViehbacherIndependent Chairman
- JPJames Paul RickeyChief Financial Officer
- MAMichele A. AndersonChief Development Officer
- NDNatalie DementVP & Head of Legal
- JMJasper M. BosIndependent Director
- DCDavid Charles LubnerIndependent Director
- ECErez ChimovitsIndependent Director
